Skip to main content
. 2021 Sep 3;12:736627. doi: 10.3389/fphar.2021.736627

FIGURE 4.

FIGURE 4

ABP enhances the anti-tumor efficacy of 5-FU against CT26 cells. (A-B) CCK-8 assay examining the effects of XAV939 (β-catenin inhibitor) and ABP on the anti-tumor efficacy of 5-FU against CT26 cells. (C) Cellular morphology of CT26 cells treated with ABP, 5-FU, and ABP + 5-FU for 24 h. Scale bar = 50 μm. (D) Transwell assays examining the enhancing effect of ABP on the anti-tumor efficacy of 5-FU against CT26 cells. Scale bar = 50 μm. (E) Wound healing assay examining the enhancing effect of ABP on the anti-tumor efficacy of 5-FU against CT26 cells. Scale bar = 250 μm. (F) Western blot examining the protein levels of β-catenin, Cyclin D1, c-Myc, COX-2, PCNA, Vimentin, E-cadherin, an GAPDH in CT26 cells treated with ABP and 5-FU. Compared with the 5-FU group, *p < 0.05, **p < 0.01, n. s., no significance.